Analysts are intrested in these 5 stocks: ( (JPM) ), ( (SBUX) ), ( (HPE) ), ( (SRPT) ) and ( (ELV) ). Here is a breakdown of their recent ratings and the rationale behind them.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
JPMorgan Chase has been the subject of mixed reviews from analysts. Glenn Thum from Phillip Securities Research downgraded the stock to a ‘Hold’ with a target price of $291. Despite a 17% drop in 2Q25 earnings year-over-year, the bank showed strength in trading, asset management, and investment banking income. However, macroeconomic uncertainties and potential interest rate cuts pose risks. The bank’s valuation appears full, with a P/E ratio of approximately 14x, higher than its 10-year average.
Starbucks has faced a downgrade from Andy Barish, who now rates the stock as ‘Sell’ with a price target of $76. The company is struggling with operational challenges and investments, particularly in China, where the business environment is becoming more competitive. Analysts see risks in the company’s U.S. sales estimates and question the strategic focus on hot beverages over cold drinks and drive-thrus. The current valuation seems unwarranted given the lack of strong evidence of fundamental improvements.
Hewlett Packard Enterprise (HPE) has received a positive outlook from Samik Chatterjee, who initiated coverage with a ‘Buy’ rating and a price target of $30. The recent acquisition of Juniper Networks positions HPE as a leader in the networking market, with significant growth potential in high-margin networking revenues. Analysts predict earnings growth driven by revenue acceleration, margin expansion, and debt reduction. The stock is seen as undervalued, with a potential bull-case valuation of over $35.
Sarepta Therapeutics has been downgraded by multiple analysts, including Gil Blum and Joseph Schwartz, to ‘Hold’ due to safety concerns and management credibility issues. The company faces challenges following the death of a patient in a gene therapy trial, raising questions about the safety of its treatments. The FDA’s potential request to pause shipments of Elevidys adds further uncertainty. Despite these issues, some analysts maintain a cautious optimism based on expected cash flows.
Elevance Health has been downgraded by Whit Mayo to ‘Hold’ with a price target of $310. The company faces strong headwinds in the healthcare sector, with no apparent earnings growth expected in 2026. Analysts express concerns about sector challenges, including volatility in Medicaid and potential risks with CAHPS. The company’s valuation has been adjusted to reflect these challenges, with a lower P/E multiple applied to future earnings estimates.